Unicycive(UNCY) - 2023 Q4 - Annual Results

Exhibit 99.1 Unicycive Announces Full Year 2023 Financial Results and Provides Business Update – Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 28, 2024 – Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the "Company" or "Unicycive"), a clinical- stage biotechnology company developing therapies for pati ...